Substance / Medication

Tavaborole

Overview

Active Ingredient
tavaborole
RxNorm CUI
1543173

Indications

Trichophyton rubrum Trichophyton mentagrophytes Tavaborole topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due toor.

Labeler: Cipla USA Inc.Updated: 2025-12-19T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Development and validation of the RP-HPLC method for quantification of tavaborole.
Prajapati Shiv Kumar, Jain Ankit, Bajpai Meenakshi · Anal Methods · 2024
PMID: 39016030Observational
Development and Validation of an HPLC-UV Method to Quantify Tavaborole During in Vitro Transungual Permeation Studies.
Tampucci Silvia, Terreni Eleonora, Burgalassi Susi et al. · J AOAC Int · 2018
PMID: 28766480Observational
Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
Aly Raza, Gupta Aditya K, Winter Tate et al. · J Drugs Dermatol · 2017
PMID: 29036255Case Report
Decoding iNOS Inhibition: A Computational Voyage of Tavaborole Toward Restoring Endothelial Homeostasis in Venous Leg Ulcers.
Velayutham Naveen Kumar, Vellapandian Chitra, Paliwal Himanshu et al. · Pharmaceuticals (Basel) · 2026
PMID: 41599735Other
Broad-spectrum antifungal activity of aniline-modified tavaborole derivatives: insights from molecular docking and bioassays.
Jiang En-Yu, Zhao Xin-Ying, Manahelohe Gizachew Mulugeta et al. · Pest Manag Sci · 2025
PMID: 40827071Other
In vitro molecular assessment ofparasitic load on human ileocecal adenocarcinoma cell culture after targeting by tavaborole (AN2690).
Mahgoub Abeer M A, Gameil Marwa Ahmed, Abdelgawad Marwa et al. · J Parasit Dis · 2025
PMID: 39975618OtherFull text (PMC)
On the mode of anti-activity of a bis(benzoxaborole) analogue of tavaborole.
Gadakh Sachin, Szczepińska Teresa, Potoczna Małgorzata et al. · Future Sci OA · 2026
PMID: 42047307
Antifungal agent tavaborole as a potential broad-spectrum serine and metallo-β-lactamases inhibitor.
Zhang Yan, Yang Siyuan, Deng Zhaoju et al. · EBioMedicine · 2025
PMID: 40367640PreclinicalFull text (PMC)
Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption.
Liu Minda, Fang Tianqi, Wang Shanshan et al. · Bioorg Chem · 2025
PMID: 40179579Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tavaborole (substance)
SNOMED CT
716264009
UMLS CUI
C3642427
RxNorm CUI
1543173
Labeler
Cipla USA Inc.

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.